MCID: GLL018
MIFTS: 57

Gallbladder Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 53 37 55 43 15
Gallbladder Carcinoma 12 55 15 17 72
Malignant Neoplasm of Gallbladder 12 72 33
Gallbladder Neoplasm 12 17 72
Carcinoma of Gallbladder 12 6
Malignant Neoplasm of Gallbladder Localized 72
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 44
Gallbladder Ca 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3121 DOID:4948
KEGG 37 H00047
ICD9CM 35 156.0
MeSH 44 D005706
SNOMED-CT 68 93810008
ICD10 33 C23
UMLS 72 C0016978 C0153452 C0235782 more

Summaries for Gallbladder Cancer

MedlinePlus : 43 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to cholangiocarcinoma and adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gallbladder Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are MAPK Pathway and DNA Damage Response (only ATM dependent). The drugs Desflurane and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and skin.

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

KEGG : 37
Gallbladder cancer (GBC) is a relatively uncommon neoplasm, however its prognosis is poor with less than a 5% 5-year survival rate. There are considerable geographic differences in its incidence and etiology. Two main pathways of GBC pathogenesis have been identified. The most common is associated with gallstones and chronic inflammation of the gallbladder, whereas a second, less frequent pathway is associated with a congenital abnormality of the pancreatic bile-duct junction, which is particularly common in Japan. TP53 inactivation has an important and early role in GBC associated with gallstones and chronic inflammation. Although KRAS mutations are rarely detected in GBC associated with gallstones, they are frequent and early events in tumors associated with congenital abnormality of the pancreatic bile-duct junction.

Wikipedia : 75 Gallbladder cancer is a relatively uncommon cancer, with an incidence of fewer than 2 cases per 100,000... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.8 UCA1 TP53 PIK3CA MALAT1 H19 ERBB2
2 adenocarcinoma 31.7 TP53 PIK3CA MALAT1 H19 ERBB2
3 bladder cancer 30.8 UCA1 TP53 MEG3 MALAT1 HOTAIR H19
4 carcinosarcoma 30.7 TP53 PIK3CA ERBB2
5 small cell cancer of the lung 30.6 TP53 PIK3CA MALAT1 HOTAIR
6 pancreatic neuroendocrine tumor 30.5 PIK3CA MEG3
7 hepatoblastoma 30.4 TP53 H19 CRNDE
8 gastric adenocarcinoma 30.4 TP53 PIK3CA HOTAIR H19 ERBB2
9 kidney cancer 30.4 TP53 MEG3 MALAT1 HOTAIR H19
10 leukemia, chronic myeloid 30.3 UCA1 MEG3 HOTAIR H19
11 retinoblastoma 30.3 TP53 MEG3 MALAT1 HOTAIR CCAT1
12 laryngeal squamous cell carcinoma 30.2 TP53 MALAT1 HOTAIR H19 CDKN2B-AS1 CCAT1
13 myeloma, multiple 30.2 UCA1 TP53 MEG3 MALAT1 HOTAIR H19
14 glioblastoma 29.9 TP53 PIK3CA MEG3 MALAT1 HOTAIR H19
15 squamous cell carcinoma 29.9 UCA1 TP53 PIK3CA MALAT1 HOTAIR H19
16 leukemia, acute myeloid 29.8 UCA1 TP53 MEG3 MALAT1 HOTAIR CDKN2B-AS1
17 renal cell carcinoma, nonpapillary 29.3 UCA1 NPTN-IT1 MALAT1 LINC-ROR HOTAIR H19
18 melanoma 29.3 UCA1 TP53 MEG3 MALAT1 LINC-ROR HOXA-AS2
19 lung cancer susceptibility 3 29.0 TP53 PIK3CA NPTN-IT1 MEG3 MALAT1 LINC-ROR
20 pancreatic cancer 28.8 UCA1 TP53 PIK3CA MEG3 MALAT1 LINC-ROR
21 cervical cancer 28.7 UCA1 TP53 PIK3CA NPTN-IT1 MEG3 MALAT1
22 hepatocellular carcinoma 28.4 UCA1 TP53 PIK3CA NPTN-IT1 MEG3 MALAT1
23 ovarian cancer 28.4 UCA1 TP53 PIK3CA MEG3 MALAT1 LINC-ROR
24 breast cancer 28.3 UCA1 TP53 PIK3CA MEG3 MALAT1 LINC-ROR
25 lung cancer 28.3 UCA1 TP53 PIK3CA MEG3 MALAT1 LINC01133
26 colorectal cancer 28.1 UCA1 TP53 PIK3CA NPTN-IT1 MEG3 MALAT1
27 gastric cancer 27.2 UCA1 TP53 PIK3CA NPTN-IT1 MEG3 MALAT1
28 adenosquamous gallbladder carcinoma 12.6
29 carcinoma of gallbladder and extrahepatic biliary tract 12.3
30 biliary tract cancer 11.6
31 gallbladder small cell carcinoma 11.6
32 bile duct cancer 11.5
33 gallbladder disease 1 10.9
34 gastric papillary adenocarcinoma 10.8 TP53 ERBB2
35 uterine corpus serous adenocarcinoma 10.8 TP53 PIK3CA ERBB2
36 breast squamous cell carcinoma 10.8 TP53 PIK3CA ERBB2
37 adult hepatocellular carcinoma 10.8 TP53 PIK3CA
38 uterine body mixed cancer 10.8 TP53 PIK3CA ERBB2
39 cholecystitis 10.8
40 uterine corpus cancer 10.8 TP53 PIK3CA ERBB2
41 rare adenocarcinoma of the breast 10.8 TP53 PIK3CA
42 esophagus adenocarcinoma 10.8 TP53 ERBB2 AFAP1-AS1
43 ovary adenocarcinoma 10.8 TP53 PIK3CA ERBB2
44 ovary epithelial cancer 10.8 TP53 PIK3CA ERBB2
45 malignant ovarian surface epithelial-stromal neoplasm 10.8 TP53 PIK3CA ERBB2
46 ovarian cancer 1 10.8 TP53 PIK3CA ERBB2
47 malignant spiradenoma 10.8 TP53 PIK3CA
48 serous cystadenocarcinoma 10.8 TP53 PIK3CA ERBB2
49 vulva squamous cell carcinoma 10.8 TP53 MEG3 MALAT1
50 cystadenocarcinoma 10.8 TP53 PIK3CA ERBB2

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desflurane Approved Phase 4 57041-67-5 42113
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3 Platelet Aggregation Inhibitors Phase 4
4 Anesthetics, Inhalation Phase 4
5 Ulipristal acetate Phase 4 126784-99-4
6
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
13
Fluorouracil Approved Phase 3 51-21-8 3385
14
leucovorin Approved Phase 3 58-05-9 143 6006
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
16
Citalopram Approved Phase 3 59729-33-8 2771
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Hormones Phase 3
20 Liver Extracts Phase 3
21 Hormone Antagonists Phase 3
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
23 Central Nervous System Depressants Phase 3
24 Cola Phase 3
25 Gastrointestinal Agents Phase 3
26 Serotonin Antagonists Phase 3
27 HIV Protease Inhibitors Phase 3
28 Anti-Inflammatory Agents Phase 3
29 Tranquilizing Agents Phase 3
30 glucocorticoids Phase 3
31 Anti-Anxiety Agents Phase 3
32 Antineoplastic Agents, Hormonal Phase 3
33 Antipruritics Phase 3
34
protease inhibitors Phase 3
35 Antipsychotic Agents Phase 3
36 BB 1101 Phase 3
37 Analgesics Phase 3
38 Anesthetics Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Narcotics Phase 3
42 Analgesics, Opioid Phase 3
43 Adjuvants, Anesthesia Phase 3
44 Trace Elements Phase 3
45 Micronutrients Phase 3
46 Antidotes Phase 3
47 Vitamins Phase 3
48 Vitamin B9 Phase 3
49 Nutrients Phase 3
50 Vitamin B Complex Phase 3

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
3 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
4 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
5 A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
6 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
7 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
8 Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial Completed NCT00391183 Phase 2, Phase 3
9 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
10 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
11 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
12 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
13 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
14 Dexamethasone Improves Postoperative Symptoms in Patients Undergoing Elective Laparoscopic Cholecystectomy: A Randomised Clinical Trial. Completed NCT01030614 Phase 3 Dexamethasone;placebo
15 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 Perioperative Chemotherapy Prior To and After Reoperation for Incidental Gallbladder Cancer - An International, Randomized Phase III Trial Recruiting NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
17 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
18 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
19 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
20 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
21 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
22 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy Active, not recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
23 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
24 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Not yet recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
25 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
26 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
27 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
28 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
29 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
30 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
31 Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer Unknown status NCT03144856 Phase 2 Apatinib
32 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
33 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
34 A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
35 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
36 A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
37 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
38 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
39 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
40 A Phase II Study of Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma, Including Carcinoma of the Gallbladder and Biliary Tract Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
41 A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
42 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
43 A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors Completed NCT00003276 Phase 2 irinotecan hydrochloride
44 Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction Completed NCT00003923 Phase 2 porfimer sodium
45 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
46 A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder Completed NCT00075504 Phase 2 triapine;gemcitabine
47 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
48 A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma Completed NCT00033462 Phase 2 erlotinib hydrochloride
49 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
50 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

MalaCards organs/tissues related to Gallbladder Cancer:

41
Liver, Lymph Node, Skin, Pancreas, Endothelial, Eye, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

19
Gallbladder

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 4679)
# Title Authors PMID Year
1
Clinical and Prognostic Significance of Neoplastic Spindle Cells in Gallbladder Cancer. 38 17
31366560 2019
2
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo. 38 17
31215139 2019
3
Unexpected Gallbladder Cancer during or after Laparoscopic Cholecystectomy: Risk Factors and Experience of Diagnosis and Treatment of 22 Cases. 38 17
31267910 2019
4
Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma. 9 38
20037816 2009
5
Expression of nm23, KAI1 and spiral computed tomography findings in primary gallbladder carcinoma. 9 38
19951590 2009
6
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase. 9 38
18946757 2008
7
Heparanase and gallbladder cancer: new insights into understanding tumor growth and invasion. 9 38
18318817 2008
8
Heparanase expression in gallbladder carcinoma and its correlation to prognosis. 9 38
17524042 2008
9
Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. 9 38
17384652 2007
10
CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. 9 38
17465213 2007
11
Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. 9 38
17287171 2007
12
Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. 9 38
17260103 2007
13
Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. 9 38
18158568 2007
14
Potential role of N-myristoyltransferase in cancer. 9 38
16846646 2007
15
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. 9 38
16820886 2006
16
Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with gallbladder carcinoma. 9 38
16794394 2006
17
Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. 9 38
16039043 2006
18
[Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo]. 9 38
16784656 2006
19
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. 9 38
16619549 2006
20
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms]. 9 38
16681930 2006
21
The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells. 9 38
16309194 2005
22
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. 9 38
15870882 2005
23
Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma. 9 38
15821928 2005
24
Expression of homeodomain protein CDX2 in gallbladder carcinomas. 9 38
15645288 2005
25
Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. 9 38
15832413 2005
26
Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. 9 38
15655836 2005
27
An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. 9 38
15578423 2005
28
[Detection of bone marrow micrometastases in patients with gallbladder cancer]. 9 38
15743160 2004
29
Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells. 9 38
15567755 2004
30
Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. 9 38
15573254 2004
31
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. 9 38
15460847 2004
32
[The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism]. 9 38
15312360 2004
33
Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. 9 38
18333072 2004
34
Potent inhibitor of N-myristoylation: a novel molecular target for cancer. 9 38
14633729 2003
35
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. 9 38
14527906 2003
36
Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. 9 38
12969785 2003
37
Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. 9 38
12692194 2003
38
[Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. 9 38
12654182 2003
39
Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. 9 38
12532418 2003
40
A case of gallbladder carcinoma diagnosed preoperatively by the detection of human telomerase reverse transcriptase mRNA in endoscopically obtained gallbladder bile. 9 38
12561014 2003
41
Mutation analysis of K-ras and beta-catenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. 9 38
12469220 2003
42
Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. 9 38
12680166 2003
43
[Subserous gallbladder carcinoma: expression of cadherine-catenine complex]. 9 38
12611235 2002
44
Expression of MMP-2,TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. 9 38
12439941 2002
45
The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. 9 38
14607700 2002
46
Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review). 9 38
12239600 2002
47
Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. 9 38
11986189 2002
48
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. 9 38
11677947 2001
49
MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. 9 38
11295067 2001
50
Increased expression of N-myristoyltransferase in gallbladder carcinomas. 9 38
10813869 2000

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6 (show all 22)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
2 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
3 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
4 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
5 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
6 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 17:7578407-7578407 17:7675089-7675089
7 PIK3CA NM_006218.4(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 3:178936091-178936091 3:179218303-179218303
8 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 17:37881332-37881332 17:39725079-39725079
9 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
10 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 12:56478854-56478854 12:56085070-56085070
11 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 12:56478854-56478854 12:56085070-56085070
12 TP53 NM_000546.5(TP53): c.535C> G (p.His179Asp) single nucleotide variant Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
13 TP53 NM_000546.5(TP53): c.536A> C (p.His179Pro) single nucleotide variant Likely pathogenic rs1057519991 17:7578394-7578394 17:7675076-7675076
14 TP53 NM_000546.5(TP53): c.722C> A (p.Ser241Tyr) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
15 TP53 NM_000546.5(TP53): c.721T> C (p.Ser241Pro) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
16 TP53 NM_000546.5(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
17 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
18 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
19 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs138729528 17:7578407-7578407 17:7675089-7675089
20 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs587780070 17:7578395-7578395 17:7675077-7675077
21 TP53 NM_000546.5(TP53): c.536A> T (p.His179Leu) single nucleotide variant Uncertain significance rs1057519991 17:7578394-7578394 17:7675076-7675076
22 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 17:7578394-7578394 17:7675076-7675076

Cosmic variations for Gallbladder Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM521 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.64 TP53 PIK3CA ERBB2
2 11.56 TP53 PIK3CA ERBB2
3 11.3 TP53 PIK3CA ERBB2
4 11.15 TP53 PIK3CA ERBB2
5 10.97 TP53 PIK3CA ERBB2
6 10.1 UCA1 TP53 MEG3 LINC-ROR HOTAIR

GO Terms for Gallbladder Cancer

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....